TD Asset Management Inc Has $53.72 Million Position in Edwards Lifesciences Co. (NYSE:EW)

TD Asset Management Inc reduced its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 4.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 569,503 shares of the medical research company’s stock after selling 27,020 shares during the quarter. TD Asset Management Inc’s holdings in Edwards Lifesciences were worth $53,721,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in EW. Sequoia Financial Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 11.4% during the first quarter. Sequoia Financial Advisors LLC now owns 9,181 shares of the medical research company’s stock worth $1,081,000 after purchasing an additional 941 shares during the period. Zions Bancorporation N.A. lifted its stake in Edwards Lifesciences by 34.7% in the first quarter. Zions Bancorporation N.A. now owns 1,738 shares of the medical research company’s stock valued at $204,000 after acquiring an additional 448 shares during the last quarter. Covestor Ltd lifted its stake in Edwards Lifesciences by 18.2% in the first quarter. Covestor Ltd now owns 1,223 shares of the medical research company’s stock valued at $144,000 after acquiring an additional 188 shares during the last quarter. Mather Group LLC. lifted its stake in Edwards Lifesciences by 53.5% in the first quarter. Mather Group LLC. now owns 7,182 shares of the medical research company’s stock valued at $846,000 after acquiring an additional 2,503 shares during the last quarter. Finally, Mackenzie Financial Corp lifted its stake in Edwards Lifesciences by 3.1% in the first quarter. Mackenzie Financial Corp now owns 655,567 shares of the medical research company’s stock valued at $77,173,000 after acquiring an additional 19,798 shares during the last quarter. 79.25% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 1.9 %

EW opened at $67.01 on Thursday. The firm’s 50-day simple moving average is $69.40 and its 200-day simple moving average is $79.88. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.45 and a current ratio of 3.28. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $94.87. The firm has a market cap of $40.64 billion, a price-to-earnings ratio of 28.64, a PEG ratio of 3.60 and a beta of 1.02.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Wednesday, October 25th. The medical research company reported $0.59 earnings per share for the quarter, hitting the consensus estimate of $0.59. Edwards Lifesciences had a net margin of 24.59% and a return on equity of 24.54%. The business had revenue of $1.48 billion for the quarter, compared to analyst estimates of $1.48 billion. During the same quarter in the prior year, the firm earned $0.61 EPS. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.51 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 6,000 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $65.30, for a total transaction of $391,800.00. Following the transaction, the vice president now owns 39,503 shares in the company, valued at approximately $2,579,545.90. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, VP Daveen Chopra sold 1,500 shares of the company’s stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $76.69, for a total transaction of $115,035.00. Following the transaction, the vice president now owns 23,950 shares in the company, valued at approximately $1,836,725.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 6,000 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $65.30, for a total transaction of $391,800.00. Following the transaction, the vice president now owns 39,503 shares in the company, valued at $2,579,545.90. The disclosure for this sale can be found here. In the last quarter, insiders have sold 179,795 shares of company stock valued at $12,724,914. 1.29% of the stock is owned by insiders.

Analysts Set New Price Targets

EW has been the subject of a number of analyst reports. Wells Fargo & Company reduced their price objective on shares of Edwards Lifesciences from $88.00 to $75.00 and set an “equal weight” rating for the company in a research note on Thursday, October 26th. Leerink Partnrs restated a “market perform” rating on shares of Edwards Lifesciences in a research note on Monday, October 16th. Royal Bank of Canada reduced their price objective on shares of Edwards Lifesciences from $86.00 to $82.00 and set an “outperform” rating for the company in a research note on Thursday, October 26th. Truist Financial reduced their price objective on shares of Edwards Lifesciences from $83.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, October 26th. Finally, Jefferies Financial Group boosted their price objective on shares of Edwards Lifesciences from $103.00 to $107.00 and gave the stock a “buy” rating in a research note on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $84.29.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.